Hummingbird Bioscience is a precision biotherapeutics company focused on discovering and developing medicines for hard-to-treat diseases in oncology and autoimmunity. The company integrates artificial intelligence, computational biology, and systems biology into its discovery platform to advance its pipeline of biotherapeutics.
Its pipeline includes several antibody-based therapies, such as the anti-HER3 antibody HMBD-001, the anti-VISTA monoclonal antibody HMBD-002, and the next-generation HER3-targeted ADC HMBD-501. The company's technical work spans the full spectrum from AI-driven target identification to the development of complex biological drugs like antibody-drug conjugates.
Hummingbird Bioscience is headquartered in Singapore, with an additional presence in Texas. The company has raised US$125 million in Series C funding to support its research and development efforts.
